Vall D Hebron Institute Of Oncology — Sponsor Intelligence | 17 EU Trials

Filter these 17 trials by condition, phase, country and more.

Open in Search →

17 Registered trials

10 Recruiting

3 Completed trials

7 Countries active

27 Unique IMPs

100% Results reported

Phase II

Phase I

Phase I (Other)

Phase III: 1 Phase II: 9 Phase I/II: 1 Phase I: 2 Phase I (Other): 4

Oversight events:

1 serious breach 2 temporary halts 1 urgent safety measure across 4 trials

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Endometrial cancer metastatic 3 Metastatic gastric cancer 2 Osteosarcoma metastatic 1 Adrenocortical carcinoma 1 Endometrial cancer 1 Retroperitoneal cancer 1 Colorectal cancer metastatic 1 Fallopian tube cancer 1 Ovarian cancer 1 BRAF V600E mutation positive 1 Endometrial cancer recurrent 1

Top IMPs

ALDESLEUKIN 1 AMIVANTAMAB 1 ATEZOLIZUMAB 1 AUTOLOGOUS TUMOUR-INFILTRATING LYMPHOCYTES 1 BELZUTIFAN 1 BEVACIZUMAB 1 CETUXIMAB 1 CYCLOPHOSPHAMIDE MONOHYDRATE 1 DOSTARLIMAB 1 ENCORAFENIB 1 FLUDARABINE PHOSPHATE 1 FUSION PROTEIN OF IL-2 AND HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST IL-2 1

All trials

17 total

A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacody… Not authorised

2024-516660-28-00 Phase I 1 country
Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT. Not authorised

2024-517002-28-00 Phase I (Other) 1 country
Moonlanding: A phase 2 study of pembrolizumab plus belzutifan, with or without lenvatinib, given before the main treatment for localized kid… Pending

2024-519673-18-00 Phase II 1 country BELZUTIFAN; LENVATINIB; PEMBROLIZUMAB
A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacody… Recruiting

2024-516660-28-01 Phase I 1 country
Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT. Recruiting

2024-517002-28-01 Phase I (Other) 1 country
Study of encorafenib plus cetuximab as rechallenge treatment of BRAF V600E-mutant metastatic colorectal cancer patients: the RefIsh trial Recruiting

2023-509564-22-00 Phase II 1 country
Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after… Recruiting

2023-506400-99-00 Phase II 3 countries ALDESLEUKIN; AUTOLOGOUS TUMOUR-INFILTRATING LYMPHOCYTES; CYCLOPHOSPHAMIDE MONOHY…
Phase II Study of Avelumab plus chemotherapy for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC). Mo… Recruiting

2024-516777-77-00 Phase II 1 country
Adjuvant therapy in high risk adrenocortical carcinoma (ADIUVO-2) Recruiting

2022-500013-32-01 Phase III 3 countries
Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, th… Recruiting

2023-509204-15-00 Phase II 1 country BEVACIZUMAB; CETUXIMAB; ENCORAFENIB
Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced … Recruiting

2024-517363-24-00 Phase II 1 country
A study to assess the safety and tolerability of next-generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) therapy. NEXTGEN-TI… Recruiting

2024-517021-12-00 Phase I (Other) 1 country
A modular multi-Basket trial to improve personalized medicine in cancer patients Recruiting

2024-514238-19-00 Phase II 6 countries AMIVANTAMAB; ATEZOLIZUMAB; FUTIBATINIB
Study Title: Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without Tremelimumab in MSS … Ended

2023-509619-10-00 Phase II 1 country
A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patient… Halted

2024-510987-22-00 Phase II 1 country OMO-103
A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and p… Ended

2024-516692-32-00 Phase I (Other) 1 country
Study to Assess the Safety, Tolerability and Efficacy of Lurbinectedin and Dostarlimab treatment in patients with endometrial cancer after d… Ended

2023-508583-30-00 Phase I/II 1 country DOSTARLIMAB; LURBINECTEDIN

Showing 1–17 of 17 trials

← All sponsors A–Z